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Background: The chronic obstructive pulmonary disease (COPD) Assessment Test (CAT) is a concise health status
measure for COPD. COPD patients have a variety of comorbidities, but little is known about their impact on quality
of life. This study was designed to investigate comorbid factors that may contribute to high CAT scores.
Methods: An observational study at Keio University and affiliated hospitals enrolled 336 COPD patients and 67
non-COPD subjects. Health status was assessed by the CAT, the St. Georges Respiratory Questionnaire (SGRQ), and
all components of the Medical Outcomes Study Short-Form 36-Item (SF-36) version 2, which is a generic measure
of health. Comorbidities were identified based on patients’ reports, physicians’ records, and questionnaires,
including the Frequency Scale for the Symptoms of Gastro-esophageal reflux disease (GERD) and the Hospital
Anxiety and Depression Scale. Dual X-ray absorptiometry measurements of bone mineral density were performed.
Results: The CAT showed moderate-good correlations with the SGRQ and all components of the SF-36. The presence
of GERD, depression, arrhythmia, and anxiety was significantly associated with a high CAT score in the COPD patients.
Conclusions: Symptomatic COPD patients have a high prevalence of comorbidities. A high CAT score should alert the
clinician to a higher likelihood of certain comorbidities such as GERD and depression, because these diseases may
co-exist unrecognized.
Trial registration: Clinical trial registered with UMIN (UMIN000003470).
Keywords: Chronic obstructive pulmonary disease, Health status, Depression, Gastro-esophageal reflux, Comorbidity,
OsteoporosisBackground
Chronic obstructive pulmonary disease (COPD) is char-
acterized by progressive and partially reversible airflow
limitation, and it is among the leading causes of mortal-
ity worldwide [1]. COPD patients manifest a range of co-
morbidities, some of which may worsen quality of life
(QOL) [2], and others may increase the risk of death [3].
According to the latest version of the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guideline,
assessment of COPD should be based on the patient’s level* Correspondence: htnakam@nifty.com
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unless otherwise stated.of symptoms, future risk of exacerbations, and the severity
of spirometric abnormalities [4]. A number of question-
naires are available that assess COPD-specific health sta-
tus, including the St. Georges Respiratory Questionnaire
(SGRQ) [5] and the Chronic Respiratory Questionnaire
[6]. These are validated and widely used for clinical trials,
but they are complex and require special software or
licenses to use, limiting their routine applicability in clin-
ical practice. A newly developed questionnaire, the COPD
Assessment Test (CAT), offers an alternative to those
complex tools [7]. It consists of eight items, each pre-
sented as a 6-point semantic differential scale, providing a
score out of 40, indicating the impact of the disease.
The usefulness of CAT has recently been reported in a
variety of clinical settings, such as for evaluating thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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habilitation [8-10]. However, relatively little is known
about the impact of comorbidities on the CAT score of
individuals with COPD. A recent study reported that the
presence of cardiovascular comorbidity did not signifi-
cantly affect the CAT score [11]. In another study, the
CAT score appeared unaffected by potentially confound-
ing comorbidities including renal failure, obesity, and
sleep disorder [8]. A recent study has shown that meta-
bolic and cardiovascular comorbidities may increase in
frequency in worse GOLD groups [12]. However, the dif-
ferential impact of other major comorbidities remains to
be investigated.
We hypothesized that symptomatic COPD patients exhi-
biting high CAT scores have unrecognized comorbidities.
Therefore, comorbid factors that might have an impact on
increasing the CAT score in COPD patients enrolled in a
well-characterized cohort study, called the Keio COPD Co-
morbidity Research (K-CCR), were evaluated.
Materials and methods
Study populations
Keio University and affiliated hospitals have established
an observational COPD cohort designed to prospectively
investigate the management of COPD comorbidities. A
total of 572 subjects were enrolled between April 2010
and December 2012, including patients who had been
diagnosed as having COPD and at risk for COPD (non-
COPD) by pulmonary physicians. Inclusion criteria con-
sisted of (1) age≧40 years old, (2) forced expiratory
volume in one second (FEV1)/forced vital capacity
(FVC) < 0.7, (3) presence of emphysematous changes on
chest computed tomography (CT) scans, and (4) chronic
respiratory symptoms with significant smoking history
(≧30 pack-years). Pulmonary function tests and chest
CT scan were performed in all participants, and the
COPD group fulfilled the criteria (1) and (2), while the
non-COPD group met the criteria (1) and either (3) or
(4) without airflow limitation (FEV1/FVC≧0.7). Excluded
were patients who had a history of lung resection sur-
gery or serious complications such as unstable cardio-
vascular or cerebral diseases and malignant tumors
under treatment. For the purpose of this study, only sub-
jects with complete data available for comorbidities (n =
403) were enrolled. All patients were clinically stable
and without exacerbations for at least one month prior
to recruitment. The protocol was approved by the ethics
committees of Keio University and the affiliated hospi-
tals, and written, informed consent was obtained from
each patient.
Assessment of clinical parameters
Spirometry was performed in all patients in a stable con-
dition using an electronic spirometer in accordance withthe guidelines of the American Thoracic Society [13].
Predicted values of spirometric measurements were de-
rived from the guidelines for pulmonary function tests
issued by the Japanese Respiratory Society [14]. Regular
treatment was not changed prior to spirometric testing.
At enrollment, a full medical and smoking history and
information about current pharmacological treatment
were obtained, and clinical examinations were performed.
Comorbid diagnoses were established using clinical history
and examination findings, supported by a review of avail-
able medical records. All of the following questionnaires
were completed by the patients themselves at home, when
in the stable state.
Questionnaires on QOL
The Japanese version of the CAT was applied for the as-
sessment of COPD-specific health status, together with
the SGRQ in Japanese [5,15,16]. The Medical Outcomes
Study Short-Form 36-Item (SF-36) version 2 was used to
assess general health status [17].
Evaluation of gastro-esophageal reflux disease (GERD)
GERD symptoms were evaluated using a self-reported
Frequency Scale for the Symptoms of GERD (FSSG)
questionnaire, consisting of 12 items. This is known to
reflect the severity of the endoscopic findings of GERD
[18], with a cut-off score of 8 points for GERD [19].
Evaluation of anxiety and depression
Depression and anxiety were assessed at baseline using
the Hospital Anxiety and Depression Scale (HADS) [20].
This is a validated screening tool for cases of depression
and anxiety in both hospitalized and primary care pa-
tients with chronic diseases, including COPD [21]. The
HADS consists of seven items for anxiety (HAD-A) and
seven items for depression (HAD-D). The scores range
from 0 to 21 for each subscale, with a score of 0–7 de-
noting a non-case, 8–10 a possible case, and 11 or
higher a probable case, which may guide referral for psy-
chological support [20].
Dual X-Ray Absorptiometry (DXA)
DXA measurements of bone mineral density (BMD)
were performed at the hip and lumbar spine using a
Hologic 4500A Discovery bone densitometer (Hologic,
Bedford, MA) for 248 of the 336 COPD patients. The T-
score was used for the evaluation of osteoporosis, in
which a T-score greater than −1 is considered normal, -1
to −2.5 osteopenia, and less than −2.5 is diagnostic of
osteoporosis [22,23].
Statistical analyses
Data are presented as means ± standard deviation (SD).
Univariate associations between CAT scores and other
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ficient, and Student’s t-test was performed to compare
mean values. Stepwise forward and backward multiple
regression analyses were performed to examine relative
contributions of comorbidities to the CAT score. In
these analyses, comorbidities were included as a categor-
ical variable. χ2 analysis was conducted to compare the
frequencies between two groups. P values less than 0.05
were considered significant. All data were analyzed using
the JMP version 9.0.2 software for Windows.
Results
Clinical features of the study population
The clinical characteristics of the study subjects are
shown in Table 1. Among the 403 subjects in this study,
67 were excluded from the COPD group based on spir-
ometry results. For the 336 COPD patients, all spiromet-
ric GOLD stages were represented, with 73 (21.7%)
patients in GOLD I, 155 (46.1%) patients in GOLD II, 84
(25.0%) patients in GOLD III, and 24 (7.1%) patients in
GOLD IV. The average age of the COPD patients was
72.4 ± 8.0 years, which was older than the non-COPD
subjects (66.1 ± 11.7 years; p < 0.001). The COPD pa-
tients included 15 never smokers. The mean CAT score
and the SGRQ total score were significantly higher in
COPD patients than in non-COPD subjects (Table 1).
Correlations of CAT, SGRQ, and SF-36 scores
To validate the CAT in a Japanese COPD population,
the correlations between the CAT and SGRQ or SF-36
were examined. The CAT score was significantly corre-
lated to the SGRQ total score and to each SGRQ com-
ponent score in COPD patients (p < 0.001) (Figure 1).
These coefficients (Pearson’s r) ranged from 0.649 (activ-
ity score) to 0.810 (total score). When the SGRQ totalTable 1 Clinical characteristics of the study groups
Non-COPD (n = 67) COPD (n = 336) p value
Male, n (%) 63 (94) 307 (91) NS
Age, years 66.1 ± 11.7 72.4 ± 8.0 <0.001
Smoking, pack-years 49.3 ± 27.9 56.7 ± 30.3 NS
Never smoker, n (%) 0 (0) 15 (4) NS
Ex-smoker, n (%) 50 (75) 282 (84) NS
Current smoker, n (%) 17 (25) 39 (12) <0.01
BMI, kg/m2 22.8 ± 4.1 22.5 ± 3.3 NS
%VC, % 94.5 ± 16.5 94.7 ± 18.6 NS
%FEV1, % 89.6 ± 16.4 61.6 ± 21.6 <0.001
CAT score 9.4 ± 6.6 12.4 ± 8.3 <0.01
SGRQ total 20.7 ± 16.4 29.4 ± 19.6 <0.001
Data are presented as means ± SD.
COPD Chronic obstructive pulmonary disease, NS Not significant, BMI Body
mass index, VC Vital capacity, FEV1 Forced expiratory volume in one second,
CAT COPD assessment test, SGRQ the St. Georges Respiratory Questionnaire.score was divided into quartiles (0≦and < 30, 30≦and <
45, 45≦and < 60, 60≦) as shown in a previous study [11],
the mean CAT score corresponded to 8.4 ± 5.0, 13.5 ±
5.0, 19.9 ± 6.7, and 27.0 ± 5.5, respectively, and clearly
distinguished between the categories (p < 0.001). The
CAT score was also significantly correlated (p < 0.001)
with all SF-36 component scores; these ranged from
r = −0.363 (bodily pain) to r = −0578 (general health)
(Figure 2).
Prevalence of comorbidities and association with CAT
The percentage of patients with each comorbidity is listed
in Table 2. Hypertension, GERD, and osteoporosis were
the three most prevalent comorbidities of the COPD pa-
tients. The prevalence of osteopenia was 33% besides
osteoporosis. The prevalence of anxiety and depression
were 7% and 10%, respectively, and the concurrent preva-
lence of both anxiety and depression was 3%. There was a
significant correlation between the HAD-A score and the
HAD-D score (data not shown, R = 0.625, p < 0.001)
among the COPD patients. The univariate analysis indi-
cated that COPD subjects with GERD, anxiety, depression,
osteoporosis, or arrhythmia had a significantly higher
CAT score than those without (Table 2).
Patients with GERD were treated with H2 blocker (9%) or
proton pump inhibitor (20%), while those with osteoporosis
were treated with bisphosphonate only in 11%. Depression
and anxiety were also overlooked and treated with medica-
tions only in 20 and 9%, respectively. In contrast more pa-
tients with arrhythmia were treated with anticoagulant
(33%), antiplatelet (18%), and other medications.
Prevalence of other comorbidities and the relationships
with the CAT score is presented as Additional file 1: Table
S1 including infrequent comorbidities (<5%) and local co-
morbidities potentially associated with treatment of COPD
(cataract, glaucoma, prostatic hypertrophy).
Multivariate comorbid determinants of the CAT score
Using the results of the univariate analysis, a stepwise
multiple regression for the CAT score was then perfor-
med including GERD, anxiety, depression, osteoporosis,
arrhythmia, age, pack-years, body mass index (BMI),
and %FEV1 as variables. The significant comorbid associa-
tions with the CAT score were GERD, depression, %FEV1,
arrhythmia, and anxiety although each contribution was
modest (as indicated by low R2 values) (Table 3). Taken to-
gether, these chief comorbidities accounted for about 20%
of the variance in the CAT score. Osteoporosis, age, pack-
years, and BMI were not significantly associated with a
higher CAT score on multivariate analysis.
The association of the CAT score with %FEV1 was
modest on univariate analysis (r = −0.258, p < 0.001).
BMI was also correlated with the CAT score (r = −0.167,
p < 0.01), whereas age and pack-years were not related to
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Figure 1 Correlation between CAT score and SGRQ scores in COPD patients (n = 336). A: SGRQ Total score, B: SGRQ Symptom score, C:
SGRQ Activity score, D: SGRQ Impact score.
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CAT score in the underweight patients (16.9 ± 9.4) (13%,
BMI < 18.5) was higher than those in the normal (12.0 ±
8.1) (65%, 18.5≦BMI<25) and overweight patients (11.1 ±
7.2) (22%, 25≦BMI). Although weight loss is associated
with various comorbidities and BMI was not related to the
CAT score on multivariate analysis, these observations
may imply certain association of low BMI with impaired
QOL in COPD patients.
Relationships between each CAT item and comorbidities
The CAT consists of eight items, each presented as a 6-
point semantic differential scale (Additional file 2: Table
S2). Thus, the multivariate comorbid determinants of
each CAT item were examined using stepwise multiple
regression analysis. As shown in Table 4, no comorbidi-
ties were associated with worsened cough or phlegm,
but the presence of GERD was associated with higher
scores of the other CAT items. The presence of depres-
sion was also significantly associated with increased
scores of all CAT items except for cough, phlegm, and
breathlessness.
Discussion
Comorbidities are frequent in subjects with COPD, but
the study of their contribution to COPD-related QOLimpairment has been limited [2,12,24]. In this study, the
validity of the Japanese version of the CAT was first con-
firmed in a well-characterized cohort of COPD patients,
since previous studies demonstrated that the SGRQ
scores also tended to be lower in Japanese COPD pa-
tients than in patients in Western countries [15]. It was
found that the CAT performed in a very similar manner
to that reported recently in other Asian countries [25].
The mean score of the COPD patients was slightly lower
than in studies in other countries [8,11], but the present
population had a higher mean %FEV1 compared to those
studies, so they were likely to have had milder disease. It
should be noted that there were some discrepancies between
the SGRQ and CAT scores in individual patients despite
good correlation between these scores at the population
level. The discrepancy in the total score appeared to be de-
rived from the differences in the activity and symptom
scores, but was within the same range as previously reported
(11). In addition the CAT scores clearly distinguished be-
tween the quartiles SGRQ score categories. The present
study provides good evidence for the validity of the CAT in
a Japanese population. To the best of our knowledge, this
was also the first comparison between the CAT (a disease-
specific measure) and the SF-36, which is a generic measure
of health (Figure 2). We therefore believe that our data are
generalizable to other languages and countries.
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Figure 2 Correlations between the CAT score and SF-36 scores in COPD patients (n = 336). A: SF-36 General health, B: SF-36 Physical
functioning, C: SF-36 Bodily pain, D: Role social, E: SF-36 Mental health, F: SF-36 Role physical, G: SF-36 Vitality, H: SF-36 Role emotional.
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sively examined, and their relationships with the CAT
score were assessed among the COPD patients. Among
a variety of comorbidities examined, the prevalence of
GERD and depression was positively related to the total
CAT score. In addition, GERD and depression were as-
sociated with 6 and 5 of the 8 CAT items, respectively,
worsening overall health status in COPD patients. This
finding is particularly important, because those diseases
may co-exist unrecognized and untreated.
The prevalence of GERD symptoms in the present
COPD population was higher than that reported previ-
ously in Western and Japanese studies [3,26]. The sig-
nificant relationships between GERD symptoms and the
CAT draw attention to the possibility that comorbid
GERD may worsen the symptoms of COPD, even
though GERD may have little impact on mortality [3].
On the other hand, no association was found betweenGERD symptoms and %FEV1 (data not shown); Mokhlesi
et al. reported a high prevalence of GERD symptoms in
patients with COPD, with a trend toward it being higher
in those with severe COPD [27]. GERD is a digestive dis-
order in which the mechanisms that keep stomach con-
tents inside the stomach malfunction, releasing acidic
stomach contents into the esophagus. Cough can then be
induced by the acid stimulus-derived vagal reflex. How-
ever, analysis of the relationships between each CAT item
and GERD symptoms did not suggest a correlation between
GERD symptoms and the extent of cough or phlegm; other
CAT items were more closely correlated with GERD in this
study (Table 4). We speculate that the occurrence of acid re-
flux, as reflected by a high FSSG score, might further worsen
the health status of COPD patients, in addition to any effect
of airflow limitation.
Depression and anxiety are well known comorbidities
and are independently associated with a higher risk of
Table 2 Prevalence of comorbidities and relationships
with the CAT score
CAT score
Comorbidity Prevalence (%) Comorbidity (+) Comorbidity (−) p value
GERD(FSSG≥ 8) 34 16.3 ± 9.1 10.5 ± 7.2 <.0001
Anxiety (HAD-A≥ 11) 7 20.0 ± 11.9 12.1 ± 7.7 <.0001
Depression (HAD-D≥ 11) 10 19.8 ± 10.2 11.8 ± 7.6 <.0001
Osteoporosis 18 14.9 ± 9.6 11.5 ± 7.6 0.013
Hypertension 36 12.4 ± 8.7 12.6 ± 8.0 NS
Diabetes mellitus 15 13.0 ± 8.3 12.4 ± 8.3 NS
Dyslipidemia 17 11.3 ± 8.9 12.7 ± 8.2 NS
Hyperuricemia 8 13.4 ± 9.4 12.4 ± 8.2 NS
Coronary artery disease 13 12.1 ± 8.0 12.5 ± 8.4 NS
Chronic heart failure 8 13.8 ± 7.1 12.4 ± 8.4 NS
Arrhythmia 11 15.2 ± 9.8 12.1 ± 8.0 0.031
Cerebral infarction 7 12.9 ± 8.5 12.5 ± 8.3 NS
Peptic ulcer 8 14.0 ± 8.9 12.3 ± 8.2 NS
Lung cancer 6 12.9 ± 7.8 12.5 ± 8.3 NS
Other malignancies 19 13.1 ± 8.2 12.4 ± 8.3 NS
Data are presented as means ± SD.
NS Not significant, CAT COPD assessment test, GERD Gastro-esophageal reflux
disease, FSSG Frequency Scale for the Symptoms of GERD, HAD-A The seven
items for anxiety of Hospital Anxiety and Depression Scale, HAD-D The seven
items for depression of Hospital Anxiety and Depression Scale.
Table 4 Comorbidities associated with the score of each
CAT item on stepwise multivariate regression analysis
CAT item Comorbidity p value Cumulative R2
Cough
None
Phlegm
None
Chest tightness
GERD (FSSG ≥ 8) <0.001 0.0901
Depression (HAD-D ≥ 11) 0.0033 0.123
Breathlessness
GERD (FSSG ≥ 8) <0.001 0.0705
Osteoporosis 0.0355 0.0876
Activity limitation
GERD (FSSG ≥ 8) <0.001 0.0926
Depression (HAD-D ≥ 11) <0.001 0.1452
Arrhythmia 0.0026 0.1773
Osteoporosis 0.0222 0.1954
Confidence to leave home
GERD (FSSG ≥ 8) <0.001 0.0631
Depression (HAD-D ≥ 11) <0.001 0.107
Osteoporosis <0.001 0.1337
Hypertension 0.0109 0.1571
Arrhythmia 0.0445 0.1714
Sleep
Depression (HAD-D ≥ 11) <0.001 0.0807
GERD (FSSG ≥ 8) 0.0033 0.1134
Anxiety (HAD-A ≥ 11) 0.01 0.1378
Arrhythmia 0.0404 0.153
Energy
GERD (FSSG ≥ 8) <0.001 0.1191
Depression (HAD-D ≥ 11) <0.001 0.1972
Arrhythmia <0.001 0.2487
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stable COPD [20], as well as a higher risk of mortality
[3]. Burgel et al. have recently reported that the presence
of depression (HAD-D ≥ 10) was the most important
contributor to the SGRQ total score in COPD [24], but
the impact on the CAT score has not yet been clarified.
In the present study, depression was found to be a
greater cofactor than anxiety for raising the CAT score
(Table 3), extending and reinforcing the importance of
psychiatric comorbidity in COPD, as previously reportedTable 3 Comorbidities associated with the CAT score on
stepwise multiple regression analysis
Comorbidity p value Cumulative R2
GERD (FSSG ≥ 8) <0.001 0.0986
Depression (HAD-D≥ 11) <0.001 0.1520
%FEV1 <0.001 0.2032
Arrhythmia 0.0030 0.2326
Anxiety (HAD-A≥ 11) 0.0188 0.2521
Osteoporosis 0.1372 0.2595
Age 0.3540 0.2623
BMI 0.4910 0.2639
Pack-year 0.6585 0.2645
CAT COPD assessment test, GERD Gastro-esophageal reflux disease, FSSG
Frequency Scale for the Symptoms of GERD, HAD-D The seven items for
depression of Hospital Anxiety and Depression Scale. HAD-A The seven items
for anxiety of Hospital Anxiety and Depression Scale, BMI Body mass index.
Anxiety (HAD-A ≥ 11) 0.0333 0.263
Abbreviations are the same as those in Table 3.[21,24]. It should be noted that the prevalence of anxiety
and depression was only 7% and 10%, respectively, in the
present study, and both are lower compared to a previ-
ous study performed in China using the same HADS
cut-off [21] or another study using other measures of de-
pression [2]. The reason for these differences is not clear,
but as shown by the CAT score and FEV1, the present
population had relatively mild disease.
Although the objective measurement of BMD on DXA
was performed only in 248 of 336 COPD patients, more
than half of the COPD patients showed reduced BMD,
with a T-score < −1.0 (51%). The prevalence of osteopor-
osis (18%, T-score < −2.5) was similar to the most recent
analysis of the Towards a Revolution in COPD Health co-
hort, with 18% in men and 30% in women [28]. Although
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peared to be related to the individual items concerning
breathlessness, activity limitation, and confidence to leave
home. This is compatible with the awareness that physical
activity is a determinant of osteoporosis. The current
problem in clinical practice is that many patients remain
undiagnosed, because patients are generally asymptomatic
until they experience a fracture [29].
The presence of other comorbidities including metabolic
diseases, cardiovascular diseases, peptic ulcer, and cancers
did not obviously contribute to raising the CAT score in
the present study. Although it has been reported that car-
diovascular disease is a major comorbidity associated with
prognosis in COPD, the prevalence of comorbid heart dis-
ease was lower compared to previous studies [30]. It is not
clear whether this is caused by ethnic or genetic differ-
ences, or by environmental differences, including socio-
economic factors. It is possible that the recruitment of
older patients may have resulted in a selection bias by
eliminating patients who had previously suffered from se-
vere cardiovascular disorders when they were younger.
Another possibility is that lower levels of current smokers
in this study (12%) may account for low rates of cardiovas-
cular diseases since smoking cessation is known to de-
crease the risk of these disorders.
There are also several limitations in this study. Dyspnea
was not separately assessed using modified British Medical
Research Council breathlessness scale, although it is one of
the most important determinants of QOL. Exacerbations
are also among important determinants of QOL in COPD
patients. However, exacerbation frequencies were not in-
cluded as factors raising CAT scores in the present study.
Roles of undiagnosed comorbidities in QOL of the patients
should be considered since this study analyzed only diag-
nosed comorbidities. Rutten et al. have suggested the im-
portance of undiagnosed left heart failure in COPD [31]. In
addition COPD patients mostly consisted of men (91%) in
this study, and the results may not apply to women.
Conclusions
Comorbidities are common in COPD patients and are
often overlooked. This study suggests that poorer health
status, as indicated by a high CAT score, may indicate
the presence of certain comorbidities, but the overall
picture suggests that COPD-specific measures such as
FEV1 and CAT do not reliably suggest the presence of
comorbidities, which should be specifically sought.Additional files
Additional file 1: Table S1. Prevalence of other comorbidities and
relationships with the CAT score.
Additional file 2: Table S2. COPD Assessment Test questionnaire.Abbreviations
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